Incyte Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INCY Nasdaq 2836 www.incyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Incyte Corporation

Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Jan 12th, 2026 10:10 am
This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth Seen - Jan 9th, 2026 9:40 am
Bull of the Day: Eli Lilly (LLY) - Jan 9th, 2026 2:00 am
Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL - Jan 8th, 2026 12:12 am
2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges - Jan 7th, 2026 9:38 pm
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Jan 6th, 2026 8:19 am
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma - Jan 5th, 2026 5:30 am
Palantir, Nvidia Lead 5 Stocks Near Buy Points Heading Into Final Days Of 2025 - Dec 27th, 2025 6:00 am
2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges - Dec 24th, 2025 9:31 pm
Is It Too Late To Consider Incyte After A 45% Rally In 2025? - Dec 23rd, 2025 7:07 am
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan - Dec 22nd, 2025 8:11 pm
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Dec 22nd, 2025 7:03 am
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma - Dec 22nd, 2025 12:44 am
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer - Dec 22nd, 2025 12:42 am
S&P 500 Posts Slight Weekly Gain, Led by Consumer Discretionary - Dec 19th, 2025 2:45 pm
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally - Dec 18th, 2025 3:12 pm
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Dec 18th, 2025 7:30 am
Incyte to Present at Upcoming Investor Conference - Dec 18th, 2025 6:00 am
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Dec 17th, 2025 9:20 am
Is Incyte Stock Outperforming the Nasdaq? - Dec 15th, 2025 6:21 am